Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Clase

Juha Andrew Clase, Mechelen BE

Patent application numberDescriptionPublished
20100298300TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES - Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following:11-25-2010
20110092497IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following:04-21-2011

Patent applications by Juha Andrew Clase, Mechelen BE

Juha Andrew Clase, Chapel-En-Le-Frith GB

Patent application numberDescriptionPublished
20090012078Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases - Novel fused pyrazine compounds are disclosed that have a formula represented by the following:01-08-2009

Juha Andrew Clase, High Peak GB

Patent application numberDescriptionPublished
20110172189Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).07-14-2011